Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1512186

This article is part of the Research Topic Molecular and Immune Influences in the Progression of Gliomas Vol II View all 7 articles

Exploring the Role of LOX Family in Glioma Progression and Immune Modulation

Provisionally accepted
Chen Liu Chen Liu 1Huilian Qiao Huilian Qiao 1Hongqi Li Hongqi Li 2Xiaolong Hu Xiaolong Hu 3Maohui Yan Maohui Yan 2Zhiguang Fu Zhiguang Fu 2Hengheng Zhang Hengheng Zhang 2YingJie Wang YingJie Wang 2*Nan Du Nan Du 1
  • 1 People's Liberation Army General Hospital, Beijing, China
  • 2 Air Force Medical Center, The Fourth Military Medical University, Beijing, China
  • 3 Beijing Geriatric Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    Background: Glioma is a major cause of mortality among central nervous system tumors, with a generally poor prognosis. The lysyl oxidase (LOX) family, a group of copper-dependent amine oxidases, has been implicated in the progression of various cancers, but its specific role in glioma and its relationship with immune infiltration remains insufficiently explored. This study aims to investigate the LOX family's expression, prognostic significance, and immune infiltration dynamics in glioma to identify potential therapeutic targets. Methods: A comprehensive analysis was conducted using public databases to assess gene expression, mutation frequency, and immune infiltration patterns related to the LOX family in glioma. The results were validated through survival analysis and immunohistochemistry. Functional assays, including EdU, Transwell, and flow cytometry, were used to evaluate glioma cell proliferation, migration, invasion, and apoptosis. Co-culture experiments with immune cells, ELISA, and a glioma transplantation model were employed to study the immune-modulatory effects of the LOX family. Gene and protein expression levels were further analyzed using qRT-PCR and Western blotting. Results: The LOX family was significantly upregulated in low-grade gliomas and strongly associated with poor clinical outcomes. Although mutation frequencies were low, the LOX family contributed to glioma progression through pathways involving metastasis, hypoxia response, angiogenesis, and immune cell infiltration. LOX expression correlated with increased infiltration of macrophages and eosinophils and decreased presence of Treg and CD8+ T cells. Knockdown of LOX genes impaired glioma cell functions, induced apoptosis, and altered immune cell behavior by reducing M2 macrophage polarization and enhancing CD8+ T cell activity. Conclusions: The LOX family is overexpressed in glioma and is associated with poor prognosis and altered immune infiltration patterns. These findings highlight the LOX family as a promising prognostic marker and therapeutic target, particularly for enhancing the effectiveness of immunotherapy in glioma treatment.

    Keywords: Glioma, LOX family, Immune infiltration, prognostic biomarker, Therapeutic target, Immune checkpoint inhibitor

    Received: 16 Oct 2024; Accepted: 11 Mar 2025.

    Copyright: © 2025 Liu, Qiao, Li, Hu, Yan, Fu, Zhang, Wang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: YingJie Wang, Air Force Medical Center, The Fourth Military Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more